Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial

Kazuma Oyama,Stephen D. Wiviott,Itamar Raz,Avivit Cahn,Erica L. Goodrich,Deepak L. Bhatt,Lawrence A. Leiter,Darren K. McGuire,John P H Wilding,Ingrid Gause-Nilsson,Ofri Mosenzon,Marc S. Sabatine,Erin A. Bohula

Abstract 14799: Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial

2020

Kazuma Oyama
Stephen D. Wiviott
Itamar Raz
Avivit Cahn
Erica L. Goodrich
Deepak L. Bhatt
Lawrence A. Leiter
Darren K. McGuire
John P H Wilding
Ingrid Gause-Nilsson
Ofri Mosenzon
Marc S. Sabatine
Erin A. Bohula

Introduction: In DECLARE-TIMI 58, the SGLT-2 inhibitor, dapagliflozin reduced the risk of the composite of cardiovascular death (CVD) or hospitalization for heart failure (HHF), and renal-specific ...

Keywords:

Internal medicine
Heart failure
TIMI
Dapagliflozin
risk stratification
cardiovascular outcomes
Type 2 Diabetes Mellitus
Cardiology
in patient
Medicine
cardiovascular death

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations